1. Home
  2. HELP vs ENLV Comparison

HELP vs ENLV Comparison

Compare HELP & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HELP

Cybin Inc. Common Stock

N/A

Current Price

$4.53

Market Cap

281.4M

Sector

Health Care

ML Signal

N/A

Logo Enlivex Therapeutics Ltd.

ENLV

Enlivex Therapeutics Ltd.

HOLD

Current Price

$1.07

Market Cap

258.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HELP
ENLV
Founded
N/A
2005
Country
Canada
Israel
Employees
50
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
281.4M
258.7M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
HELP
ENLV
Price
$4.53
$1.07
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$95.00
$13.00
AVG Volume (30 Days)
1.1M
538.3K
Earning Date
07-01-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.41
$0.66
52 Week High
$8.55
$2.10

Technical Indicators

Market Signals
Indicator
HELP
ENLV
Relative Strength Index (RSI) 35.50 46.57
Support Level $4.47 $0.99
Resistance Level $4.95 $1.07
Average True Range (ATR) 0.34 0.08
MACD -0.03 -0.00
Stochastic Oscillator 7.19 13.11

Price Performance

Historical Comparison
HELP
ENLV

About HELP Cybin Inc. Common Stock

Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.

About ENLV Enlivex Therapeutics Ltd.

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

Share on Social Networks: